INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS : Ten-Year Follow-Up
PURPOSE: To assess the long-term efficacy of intravitreal antivascular endothelial growth factor injections (IVI), alone or in combination with verteporfin photodynamic therapy (IVI/PDT), for management of choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome (POHS).
METHODS: Retrospective, comparative, interventional case series analyzing 82 eyes in 74 patients treated with either IVI or IVI/PDT for presumed ocular histoplasmosis syndrome choroidal neovascularization from January 2006 to January 2021.
RESULTS: The average logarithm of the minimum angle of resolution VA in year 5 was 0.40 (20/50) and 0.52 (20/67) for IVI versus IVI/PDT groups, respectively ( P = 0.33), and in year 10 was 0.53 (20/58) and 0.64 (20/86), respectively ( P = 0.50). The average number of annual injections over the first 5 years of follow-up was 3.3 versus 1.7 for IVI versus IVI/PDT groups, respectively ( P < 0.001), and over 10 years was 3.3 versus 1.6, respectively ( P < 0.001). Treatment-free interval of 5 years was reached by 39% versus 60% in IVI versus IVI/PDT groups, respectively ( P = 0.95).
CONCLUSION: Our study found both IVI and IVI/PDT to be effective in long-term management of presumed ocular histoplasmosis syndrome choroidal neovascularization, with a fewer number of annual injections and longer treatment-free interval in the combination group. However, given the limitations of a retrospective study, a prospective randomized study is necessary to determine whether the addition of PDT significantly decreases treatment burden.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Retina (Philadelphia, Pa.) - 42(2022), 8 vom: 01. Aug., Seite 1568-1573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dudenhoefer, Nicholas E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis Inhibitors |
|---|
| Anmerkungen: |
Date Completed 27.07.2022 Date Revised 29.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/IAE.0000000000003488 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343978520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343978520 | ||
| 003 | DE-627 | ||
| 005 | 20231226021710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/IAE.0000000000003488 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343978520 | ||
| 035 | |a (NLM)35877968 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dudenhoefer, Nicholas E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS |b Ten-Year Follow-Up |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2022 | ||
| 500 | |a Date Revised 29.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To assess the long-term efficacy of intravitreal antivascular endothelial growth factor injections (IVI), alone or in combination with verteporfin photodynamic therapy (IVI/PDT), for management of choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome (POHS) | ||
| 520 | |a METHODS: Retrospective, comparative, interventional case series analyzing 82 eyes in 74 patients treated with either IVI or IVI/PDT for presumed ocular histoplasmosis syndrome choroidal neovascularization from January 2006 to January 2021 | ||
| 520 | |a RESULTS: The average logarithm of the minimum angle of resolution VA in year 5 was 0.40 (20/50) and 0.52 (20/67) for IVI versus IVI/PDT groups, respectively ( P = 0.33), and in year 10 was 0.53 (20/58) and 0.64 (20/86), respectively ( P = 0.50). The average number of annual injections over the first 5 years of follow-up was 3.3 versus 1.7 for IVI versus IVI/PDT groups, respectively ( P < 0.001), and over 10 years was 3.3 versus 1.6, respectively ( P < 0.001). Treatment-free interval of 5 years was reached by 39% versus 60% in IVI versus IVI/PDT groups, respectively ( P = 0.95) | ||
| 520 | |a CONCLUSION: Our study found both IVI and IVI/PDT to be effective in long-term management of presumed ocular histoplasmosis syndrome choroidal neovascularization, with a fewer number of annual injections and longer treatment-free interval in the combination group. However, given the limitations of a retrospective study, a prospective randomized study is necessary to determine whether the addition of PDT significantly decreases treatment burden | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Endothelial Growth Factors |2 NLM | |
| 650 | 7 | |a Photosensitizing Agents |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Noble, Carl W |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Robert E |e verfasserin |4 aut | |
| 700 | 1 | |a Riemann, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Sisk, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Hutchins, Robert K |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Daniel M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Retina (Philadelphia, Pa.) |d 1981 |g 42(2022), 8 vom: 01. Aug., Seite 1568-1573 |w (DE-627)NLM012598550 |x 1539-2864 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:8 |g day:01 |g month:08 |g pages:1568-1573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/IAE.0000000000003488 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 8 |b 01 |c 08 |h 1568-1573 | ||